We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , Elevance Health, Inc. (ELV - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Sony Group Corp. (SONY - Free Report) and General Mills, Inc. (GIS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stocks for JPMorgan Chase, Elevance Health and Vertex Pharmaceuticals
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Elevance Health, Inc. and Vertex Pharmaceuticals Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry over the past six months (+22.0% vs. +7.8%). The company's fourth-quarter 2022 results show impacts of higher rates, decent loan demand and a rise in expenses and provisions. Opening new branches, strategic buyouts and global expansion will keep driving financials. Higher rates and a steady loan demand will aid net interest income (NII) growth.
The Zacks analyst estimates for NII (managed) show a CAGR of 6.2% by 2025. Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to make fee income growth challenging. We expect non-interest income (managed) to be relatively stable this year.
Steadily rising costs is a major woe, and we expect the same to rise 5.8% in 2023. Given the possibility of an economic slowdown, provisions are likely to keep rising, with we projecting the same to jump 53.1% in 2023.
Elevance Health shares have outperformed the Zacks Medical Services industry over the past year (+11.5% vs. -18.4%). The company's improving top line can be attributed to premium rate increases and higher memberships. Acquisitions, collaborations and product expansions have enabled the company to strengthen its business portfolio.
Its well-performing Medicare and Medicaid businesses, coupled with several contract wins, are expected to drive its membership going ahead. Growing premiums, stemming from rate increases are aiding the company's results. Elevance Health utilizes excess capital to boost shareholder value.
However, the company's escalating expenses continue to put pressure on margins. Its declining cash flows are also concerning. ELV's balance sheet with a massive debt of more than $22.3 billion can affect financial flexibility. As such, the stock warrants a cautious stance.
Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+27.6% vs. -6.7%). The company's cystic franchise sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher.
Vertex reported double-digit revenue growth over the last several years. Vertex has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with multiple clinical milestones in 2023. Multiple late-stage projects have established proof of concept.
Vertex faces only minimal competition in its core CF franchise. However, Vertex's dependence on just the CF franchise for commercial revenues is a concern. Vertex's non-CF programs carry significant risk, which is a concern.
Other noteworthy reports we are featuring today include Sony Group Corp. and General Mills, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights JPMorgan Chase, Elevance Health, Vertex Pharmaceuticals, Sony Group and General Mills
For Immediate Release
Chicago, IL – February 22, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , Elevance Health, Inc. (ELV - Free Report) , Vertex Pharmaceuticals Inc. (VRTX - Free Report) , Sony Group Corp. (SONY - Free Report) and General Mills, Inc. (GIS - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Stocks for JPMorgan Chase, Elevance Health and Vertex Pharmaceuticals
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., Elevance Health, Inc. and Vertex Pharmaceuticals Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of JPMorgan Chase have outperformed the Zacks Banks - Major Regional industry over the past six months (+22.0% vs. +7.8%). The company's fourth-quarter 2022 results show impacts of higher rates, decent loan demand and a rise in expenses and provisions. Opening new branches, strategic buyouts and global expansion will keep driving financials. Higher rates and a steady loan demand will aid net interest income (NII) growth.
The Zacks analyst estimates for NII (managed) show a CAGR of 6.2% by 2025. Yet, the volatile nature of the capital markets business and higher mortgage rates are likely to make fee income growth challenging. We expect non-interest income (managed) to be relatively stable this year.
Steadily rising costs is a major woe, and we expect the same to rise 5.8% in 2023. Given the possibility of an economic slowdown, provisions are likely to keep rising, with we projecting the same to jump 53.1% in 2023.
(You can read the full research report on JPMorgan Chase here >>>)
Elevance Health shares have outperformed the Zacks Medical Services industry over the past year (+11.5% vs. -18.4%). The company's improving top line can be attributed to premium rate increases and higher memberships. Acquisitions, collaborations and product expansions have enabled the company to strengthen its business portfolio.
Its well-performing Medicare and Medicaid businesses, coupled with several contract wins, are expected to drive its membership going ahead. Growing premiums, stemming from rate increases are aiding the company's results. Elevance Health utilizes excess capital to boost shareholder value.
However, the company's escalating expenses continue to put pressure on margins. Its declining cash flows are also concerning. ELV's balance sheet with a massive debt of more than $22.3 billion can affect financial flexibility. As such, the stock warrants a cautious stance.
(You can read the full research report on Elevance Health here >>>)
Shares of Vertex Pharmaceuticals have outperformed the Zacks Medical - Biomedical and Genetics industry over the past year (+27.6% vs. -6.7%). The company's cystic franchise sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher.
Vertex reported double-digit revenue growth over the last several years. Vertex has a broad clinical non-CF pipeline across six disease areas, which are progressing rapidly with multiple clinical milestones in 2023. Multiple late-stage projects have established proof of concept.
Vertex faces only minimal competition in its core CF franchise. However, Vertex's dependence on just the CF franchise for commercial revenues is a concern. Vertex's non-CF programs carry significant risk, which is a concern.
(You can read the full research report on Vertex Pharmaceuticals here >>>)
Other noteworthy reports we are featuring today include Sony Group Corp. and General Mills, Inc.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.